Zydus Lifesciences Limited Stock price

Equities

ZYDUSLIFE

INE010B01027

Pharmaceuticals

Market Closed - NSE India S.E. 05:10:48 22/02/2024 pm IST 5-day change 1st Jan Change
904.3 INR +1.17% Intraday chart for Zydus Lifesciences Limited +2.88% +31.21%
Sales 2024 * 192B 2.32B Sales 2025 * 209B 2.53B Capitalization 905B 10.93B
Net income 2024 * 35.31B 426M Net income 2025 * 36.72B 443M EV / Sales 2024 * 4.64 x
Net cash position 2024 * 13.55B 164M Net cash position 2025 * 34.97B 422M EV / Sales 2025 * 4.15 x
P/E ratio 2024 *
25.9 x
P/E ratio 2025 *
24.4 x
Employees 23,026
Yield 2024 *
0.66%
Yield 2025 *
0.67%
Free-Float 24.62%
More Fundamentals * Assessed data
Dynamic Chart
Zydus Lifesciences Gets US FDA Final Approval for Generic Chest Pain Drug MT
Zydus Lifesciences Limited Receives Final Approval from the United States Food and Drug Administration for Isosorbide Mononitrate Extended-Release, Tablets USP, 30 mg, 60 mg, and 120 mg CI
Jefferies Adjusts Zydus Lifesciences’ Price Target to INR750 From INR660, Keeps at Hold MT
Zydus Lifesciences' Consolidated Net Profit Increases in Fiscal Q3; Shares Jump 7% MT
Transcript : Zydus Lifesciences Limited, Q3 2024 Earnings Call, Feb 09, 2024
Zydus Lifesciences Gets Tentative US FDA Approval for Dexamethasone MT
India's Zydus Lifesciences beats Q3 profit estimates; approves shares buyback RE
Zydus Receives Tentative Approval from the USFDA for Dexamethasone Tablets USP, 1 mg CI
Zydus Lifesciences Limited announces an Equity Buyback for 5,970,149 shares, representing 0.59% for INR 6,000 million. CI
Zydus Lifesciences Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023 CI
Indian shares set for a muted start, tracking Asian peers RE
Zydus Lifesciences Limited authorizes a Buyback Plan. CI
Zydus Lifesciences Gets US FDA's Final Approval for Dexamethasone Tablets MT
Zydus Lifesciences Limited Receives Final Approvals from the United States Food and Drug Administration to Manufacture and Market Dexamethasone Tablets USP, 2 Mg CI
Zydus Lifesciences Limited's Board intends to launch an Equity Buyback on February 9, 2024. CI
More news
1 day+1.17%
1 week+2.88%
Current month+18.86%
1 month+24.02%
3 months+40.85%
6 months+38.93%
Current year+31.21%
More quotes
1 week
880.35
Extreme 880.35
912.80
1 month
706.60
Extreme 706.6
912.80
Current year
686.00
Extreme 686
912.80
1 year
452.20
Extreme 452.2
912.80
3 years
319.00
Extreme 319
912.80
5 years
202.00
Extreme 202
912.80
10 years
174.42
Extreme 174.42
912.80
More quotes
Managers TitleAgeSince
Chief Executive Officer 44 01/97/01
Director of Finance/CFO - -
Chairman 71 15/95/15
Members of the board TitleAgeSince
Director/Board Member 72 06/18/06
Chairman 71 15/95/15
Director/Board Member 69 01/97/01
More insiders
Date Price Change Volume
22/24/22 904.3 +1.17% 940 029
21/24/21 893.8 -0.22% 795,916
20/24/20 895.8 -1.30% 1,009,373
19/24/19 907.6 +1.75% 1,032,096
16/24/16 891.9 +1.47% 826,132

Delayed Quote NSE India S.E., February 22, 2024 at 05:10 pm IST

More quotes
Zydus Lifesciences Ltd. is an India-based life sciences company. The Company is engaged in the research and development, manufacturing, marketing and selling of finished dosage human formulations, such as generics and specialty formulations, including biosimilars and vaccines; active pharmaceutical ingredients (APIs); animal healthcare products, and consumer wellness products. Its products include Bilypsa (saroglitizar), Oxemia (desidustat), Ujvira (biosimilar Kadcyla), and Exemptia. It offers Bilypsa drug for non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). Desidustat is an oral, small molecule hypoxia-inducible factor-prolyl hydroxylase (HIF-PH) inhibitor, which is used for the treatment of anemia in chronic kidney disease (CKD) patients. It is also developing an oral small molecule ZYIL1, targeted at selectively suppressing inflammation caused by the NLRP3 inflammasome. Its ZyCoV-D is a plasmid deoxyribonucleic acid (DNA) vaccine for COVID-19.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
30
Last Close Price
893.8 INR
Average target price
793.2 INR
Spread / Average Target
-11.26%
Consensus
  1. Stock
  2. Equities
  3. Stock Zydus Lifesciences Limited - NSE India S.E.
+229% on MICROSOFT CORPORATION since our purchase on January 11, 2019
Replicate our performance
fermer